Novo Nordisk A/s Share Price: NVO (Novo Nordisk A/s) Stock Price Today & Updates | INDmoney

Question 1

What is Novo Nordisk A/s share price today?

Accepted Answer

Novo Nordisk A/s (NVO) share price today is {{live_price}}.

Question 2

Can Indians buy Novo Nordisk A/s shares?

Accepted Answer

Yes, Indians can invest in the Novo Nordisk A/s (NVO) from India.

With INDmoney, you can buy Novo Nordisk A/s at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Novo Nordisk A/s at zero transaction cost.

Question 3

How can I buy Novo Nordisk A/s shares from India?

Accepted Answer

It is very easy to buy Novo Nordisk A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Novo Nordisk A/s be purchased?

Accepted Answer

Yes, you can buy fractional shares of Novo Nordisk A/s with INDmoney app.

Question 5

What are the documents required to start investing in Novo Nordisk A/s stocks?

Accepted Answer

To start investing in Novo Nordisk A/s, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Novo Nordisk A/s

Accepted Answer

Today’s highest price of Novo Nordisk A/s (NVO) is {{1_rba_end}}.

Today’s lowest price of Novo Nordisk A/s (NVO) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Novo Nordisk A/s

Accepted Answer

Today's market capitalisation of Novo Nordisk A/s NVO is 472.8B

Question 8

What is the 52 Week High and Low Range of Novo Nordisk A/s

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Novo Nordisk A/s is down from its 52 Week High?

Accepted Answer

Novo Nordisk A/s (NVO) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Novo Nordisk A/s is up from its 52 Week low?

Accepted Answer

Novo Nordisk A/s (NVO) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Novo Nordisk A/s?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Novo Nordisk A/s

Accepted Answer

Mr. Lars Fruergaard Jorgensen is the current Chief Executive Officer (CEO) of Novo Nordisk A/s.

Period	Novo Nordisk A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-22.35%	-7.3%	0.0%
6 Months	-21.64%	-0.2%	0.0%
1 Year	1.15%	9.9%	0.0%
3 Years	94.25%	8.8%	-24.1%

Market Capitalization	472.8B
Book Value	$27.07
Dividend Share	9.9
Dividend Yield	1.42%
Earnings Per Share (EPS)	2.99
PE Ratio	34.03
PEG Ratio	1.54
Wall Street Target Price	941.311

Profit Margin	35.01%
Operating Margin TTM	47.43%

Return On Assets TTM	21.47%
Return On Equity TTM	88.73%

Revenue TTM	270.6B
Revenue Per Share TTM	60.7
Quarterly Revenue Growth YOY	21.4%
Gross Profit TTM	148.5B
EBITDA	127.4B
Diluted Eps TTM	2.99
Quarterly Earnings Growth YOY	0.22

Novo Nordisk A/s (NVO)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Increasing Revenue

Increasing Net Profit

Vs ABBV

Institutional Holdings

Corporate Announcements

Novo Nordisk A/s Dividends March,2024

Company Information

Discover More

FAQs

EPS Estimate Current Year	22.7
EPS Estimate Next Year	27.89
EPS Estimate Current Quarter	0.7
EPS Estimate Next Quarter	0.89

	FY18	Y/Y Change
Revenue	17.0B	↑ 0.12%
Net Income	5.9B	↑ 1.31%
Net Profit Margin	34.54%	↑ 0.4%

	FY19	Y/Y Change
Revenue	18.1B	↑ 9.11%
Net Income	5.8B	↑ 0.84%
Net Profit Margin	31.92%	↓ 2.62%

	FY20	Y/Y Change
Revenue	20.7B	↑ 4.04%
Net Income	6.9B	↑ 8.18%
Net Profit Margin	33.19%	↑ 1.27%

	FY21	Y/Y Change
Revenue	21.4B	↑ 10.91%
Net Income	7.3B	↑ 13.33%
Net Profit Margin	33.92%	↑ 0.73%

	FY22	Y/Y Change
Revenue	25.2B	↑ 25.68%
Net Income	7.9B	↑ 16.27%
Net Profit Margin	31.38%	↓ 2.54%

	FY23	Y/Y Change
Revenue	34.0B	↑ 31.26%
Net Income	12.3B	↑ 50.71%
Net Profit Margin	36.03%	↑ 4.65%

	Q2 FY23	Q/Q Change
Revenue	7.9B	↑ 1.75%
Net Income	2.8B	↓ 1.95%
Net Profit Margin	35.78%	↓ 1.35%

	Q3 FY23	Q/Q Change
Revenue	8.4B	↑ 8.16%
Net Income	3.2B	↑ 15.7%
Net Profit Margin	38.27%	↑ 2.49%

	Q4 FY23	Q/Q Change
Revenue	9.6B	↑ 12.14%
Net Income	3.2B	↓ 2.29%
Net Profit Margin	33.35%	↓ 4.92%

	FY18	Y/Y Change
Total Assets	16.9B	↑ 8.22%
Total Liabilities	9.0B	↑ 12.16%

	FY19	Y/Y Change
Total Assets	18.7B	↑ 13.4%
Total Liabilities	10.1B	↑ 15.42%

	FY20	Y/Y Change
Total Assets	23.7B	↑ 15.37%
Total Liabilities	13.3B	↑ 19.96%

	FY21	Y/Y Change
Total Assets	29.6B	↑ 34.22%
Total Liabilities	18.8B	↑ 51.67%

	Q1 FY24	Q/Q Change
Revenue	9.5B	↓ 0.78%
Net Income	3.7B	↑ 15.68%
Net Profit Margin	38.88%	↑ 5.53%

	Q2 FY24	Q/Q Change
Revenue	9.8B	↑ 4.15%
Net Income	2.9B	↓ 21.08%
Net Profit Margin	29.46%	↓ 9.42%

	Q3 FY24	Q/Q Change
Revenue	71.3B	↑ 4.78%
Net Income	27.3B	↑ 36.16%
Net Profit Margin	38.28%	↑ 8.82%

	FY18	Y/Y Change
Operating Cash Flow	6.8B	↑ 8.38%
Investing Cash Flow	-1.8B	↑ 83.84%
Financing Cash Flow	-5.3B	↓ 3.27%

	FY19	Y/Y Change
Operating Cash Flow	7.0B	↑ 4.85%
Investing Cash Flow	-1.7B	↓ 4.73%
Financing Cash Flow	-5.3B	↑ 2.79%

	FY20	Y/Y Change
Operating Cash Flow	8.5B	↑ 11.05%
Investing Cash Flow	-3.7B	↑ 94.94%
Financing Cash Flow	-5.3B	↓ 9.13%

	FY21	Y/Y Change
Operating Cash Flow	8.4B	↑ 5.87%
Investing Cash Flow	-4.8B	↑ 40.87%
Financing Cash Flow	-3.9B	↓ 20.94%

	FY22	Y/Y Change
Operating Cash Flow	11.2B	↑ 43.43%
Investing Cash Flow	-3.5B	↓ 21.16%
Financing Cash Flow	-7.4B	↑ 103.18%

	Q2 FY23	Q/Q Change
Operating Cash Flow	4.2B	↓ 4.15%
Investing Cash Flow	-2.3B	↑ 139.69%
Financing Cash Flow	-1.8B	↓ 38.95%

	Q3 FY23	Q/Q Change
Operating Cash Flow	5.9B	↑ 43.35%
Investing Cash Flow	-4.2B	↑ 83.12%
Financing Cash Flow	-2.8B	↑ 57.53%

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novo Nordisk A/s	-7.34%	-21.64%	1.15%	94.25%	273.55%
Eli Lilly And Company	-16.21%	-7.41%	26.45%	187.29%	536.77%
Johnson & Johnson	-3.55%	7.47%	2.57%	-2.53%	13.11%
Merck & Co. Inc.	-4.62%	-21.34%	-2.22%	25.29%	15.73%
Abbvie Inc	-5.8%	13.91%	27.22%	51.88%	101.63%

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novo Nordisk A/s	Buy	$472.8B	273.55%	34.03	35.01%
Eli Lilly And Company	Buy	$711.9B	536.77%	80.9	20.48%
Johnson & Johnson	Buy	$370.8B	13.11%	25.45	16.74%
Merck & Co. Inc.	Buy	$252.6B	15.73%	20.89	19.23%
Abbvie Inc	Buy	$303.5B	101.63%	59.84	9.22%

Organization	Novo Nordisk A/s
Employees	71880
CEO	Mr. Lars Fruergaard Jorgensen
Industry	Health Technology